Nursing Review Issue 2 | Mar-Apr 2018 | Page 21

clinical practice “The students in this study agreed they had a role in pressure injury prevention and that it should be a priority. The greatest concern about pressure injury prevention attitudes is personal competency beliefs,” the study said. It added that the findings highlight the need for a comprehensive approach to increase students’ knowledge in this area and for students to have adequate experiences in clinical units with a high focus on pressure injury prevention. The authors also called on educators, registered nurses and nurse supervisors to involve students in pressure injury prevention. Nursing Review spoke with lead author Professor Kim Usher, head of the School of Health at UNE, to discuss the ways nurses can help students improve their approach to pressure injuries and what changes are needed in training organisations. give the best quality of care to patients. And pressure injuries are something that cause a lot of concern and distress to the patient. They can also lead to a number of complications and can extend hospitalisation, so they add a lot of costs to our healthcare system. In some countries, the costs have become so great that they’ve started to penalise hospitals that report high numbers of pressure injuries. NR: What are your concerns about the lack of pressure injury knowledge? Well, importantly, students did show that they had some knowledge areas covered: nutrition, risk assessment, and the aetiology and development of pressure injuries. KU: Pressure injuries are an indicator of quality care, so we should be aiming to What were some of the important aspects of pressure injury prevention that students weren’t fully across? For me, the biggest concern is that a lot of students in this study lacked knowledge about prevention. They also lacked the ability to accurately assess the levels of pressure injuries. On the flip side, in which areas did you see high scores? Also, students scored quite high on attitudes, which is similar to findings in other countries. That means Australian nursing students have a good attitude towards pressure injury prevention. They see it as part of their role. Unfortunately, students scored low on confidence. They tended not to feel confident that they were able to reduce pressure injuries or that they knew the strategies to do so. How can pressure injury training be improved? Nursing curricula across Australia need to have more of a focus on pressure injuries, on strategies to assess and prevent them. Also, I’d like to see that when our students go on clinical – as we found students who’d been in more varied areas of clinical had better knowledge of pressure injury prevention strategies – I’d like to see it mandated that students have to experience a number of different areas of clinical during their undergraduate nursing program. ■ at www.seqirus.com.au/PIs given at the same time as other vaccines although no clinical data on concomitant administration with other vaccines are available. Immunisation should be carried out on separate limbs. It should be noted that any adverse reactions might be intensified. VERY COMMON AND COMMON ADVERSE EVENTS: Local reactions, including redness, swelling, induration, pain at the injection site and ecchymosis. Systemic reactions including fever, malaise, shivering, fatigue, headache, sweating, myalgia, arthralgia. These reactions usually disappear within 1-2 days without treatment. DOSAGE AND USAGE: A single 0.5mL dose should be administered by intramuscular injection into the deltoid muscle. Bring FLUAD ® to room temperature prior to injection. Gently shake before use. After shaking, the normal appearance of FLUAD ® is a milky-white suspension. Based on Approved Product Information 16 November 2017. NIP = National Immunisation Programme. REFERENCES: 1. FLUAD Approved Product Information, November 2017. 2. Media Release: Prime Minister, Minister for Health, 18th February 2018. Available at: https://www.pm.gov.au/media/ground-breaking-flu-vaccines-protect-millions-aussies Accessed 21 March 2018. 3. Seqirus Data on File. Seqirus (Australia) Pty Ltd. ABN 66 120 398 067, 63 Poplar Road Parkville, Victoria 3052. www.seqirus.com.au. Medical Information: 1800 642 865. FLUAD ® is a registered trademark and Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: March 2018. SEQ/FTIV/0318/0006. 14720. • FLUAD is tailored to help protect those aged 65 years and over against influenza • Over 90 million doses distributed and registered in over 30 countries worldwide ® 1 3 influenza vaccine, adjuvanted influenza vaccine, adjuvanted NO W AVA IL A B L E O N NIP 2 1 27/3/18 2:32 pm nursingreview.com.au | 19